- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04208711
Role of PLA2G1B During HIV Infection (PREDIACC)
Study of the Role of PLA2G1B in the Immunopathogenicity by Action on CD4 T Cells During HIV Infection
Study Overview
Detailed Description
Antiretroviral therapy in HIV-infected patients has progressed significantly over the past two decades.
Viral replication in patients who are complicit in their treatment regimen is greatly reduced below detection limits (quantification) by current and approved laboratory tests. However, the persistence of residual (plasma) replication of the virus creates an inflammatory state associated with certain pathologies, accelerated aging and premature mortality. If treatment is discontinued for any reason, viral replication resumes within a few weeks in almost all patients.
Alternative infections of inflammatory pathways in HIV can also play a critical role in the inflammatory process suppressed by treatment. Members of the phospholipase A2 family can hydrolyze phospholipid molecules at the sn-2 position, making it a question about lipid moieties. One of the members, the phospholipase A2 group1B (PLA2G1B), is found in the plasma of HIV-infected patients who are not receiving antiretroviral therapy. Ex vivo, this enzyme is able to induce a purified CD4 lymphocyte energy from donors, as well as by inducing the lack of response to IL-7 (interleukin-7). In the long term, loss of response to IL-7 induces CD4 lymphopenia. Therefore, PLA2G1B must play an important role in the mechanism leading to HIV-infected patients becoming immunodeficient.
At the clinical level, we found that PLA2G1B activity increases in all HIV-infected patients and decreases after ARV treatment. On the other hand, for patients who are able to eliminate the HIV virus on therapy but whose immunological response remains low, PLA2G1B activity remains high. More interestingly, in "HIV Elite Controller" patients, PLA2G1B activity is not found in their plasma. Overall, there is a correlation between the different clinical groups (viremic not on therapy, ARV and virus removal with robust CD4+ T-cell response, virus removal with suboptimal CD4+ T-cell response and "HIV Elite Controller") and the activity level of PLA2G1B in their plasma.
The purpose of this study, more generally, is to study the role of PLA2G1B in CD4 lymphocytes and to analyze the reversion of its effects in the immunopathogenicity of HIV infection.
In the main study, 15 patients will be included. The analysis of the first 7 patients will in addition meet the objectives of the study, to determine the test that will allow the follow-up of the 8 other patients after ARV treatment. The participation of the 7 patients in the study is limited to 1 (one) day.
In the sub-study, the last 8 patients following their inclusion in the main study will enter a follow-up phase of 12 months after they are put on ARV treatment. The total duration of participation for the 8 patients will be 13 months.
The main study is carried out by taking 50 mL of total blood and in the sub-study, 30mL of blood sample will be taken during the follow-up visit (at M1, M3, M6, M9 and 12 Months) after ARV treatment.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: THEZE
- Phone Number: +33(0) 1 45 68 86 00
- Email: jacques.theze@diaccurate.com
Study Contact Backup
- Name: DELIGNE
- Phone Number: +33(0)1 44 38 93 93
- Email: claire.deligne@diaccurate.com
Study Locations
-
-
-
Paris, France, 75014
- Recruiting
- CIC 1417 Cochin Pasteur, hôpital Cochin
-
Contact:
- LAUNAY
- Email: odile.launay@aphp.fr
-
Contact:
- KONATE
- Phone Number: +33(0) 1 58 41 33 68
- Email: eleine.konate@aphp.fr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Participant aged 18 to under 70
- Participant having signed the written and informed consent;
- Patient with HIV-1 infection documented by a positive HIV western blot positive (infected patients> 6 months, CD4 count> 350 / mm3 and HIV RNA <100.000 copies / mL) naive to any ARV treatment Anti-HIV antibody positive and an optical density <1.0, as determined by enzyme immunoassay, with no significant risk of clinical events
- Appropriate laboratory data: hemoglobin> 9 g / dL, absolute neutrophil count ≥1000 / μL, platelets ≥50,000 / μL, bilirubin ≤ 1.5 X upper limit of normal (ULN) or ≤3 X ULN serum creatinine ≤ 1.5 X ULN, alanine amino transferase (ALT) or aspartate amino transferase (AST) ≤ 3 X ULN;
- ECOG (Eastern Cooperative Oncology Group) performance status scale ≤2
- Subject benefiting from a French social security scheme, or affiliated to such a scheme
Exclusion Criteria:
- History of inflammatory disease such as rheumatoid arthritis, lupus, Crohn's disease, ulcerative colitis
- Concomitant use of systemic or topical corticosteroids for the treatment of skin diseases. However, topical steroids and oral steroids (≤10 mg prednisone equivalent / day) are permitted if the patient has received a stable dose with stable symptoms for at least 4 weeks before inclusion in the study.
- Major surgery <4 weeks before inclusion in the study.
- A stem cell transplant.
- History of other malignancies in the last three years except Kaposi controlled.
- Infection known by hepatitis C or B virus (HCV or HBV)
- Congestive heart failure, class III or IV, according to the criteria of the New York Heart Association (NYHA).
- Vulnerable population (minors, pregnant, parturient or nursing women, persons under guardianship or trusteeship, or deprived of liberty by a judicial or administrative decision, under the protection of justice)
- Patients with dementia or altered mental states who would not understand and provide an informed consent document
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: positive HIV patient not treated by ARV yet
Before starting HIV treatment, 15 patients will be included in the study and 50mL of whole blood will be taken. After treatment initiation 8 of the 15 patients will entered in the follow-up phase for 1 year (5 followup visit, M1, M3, M6, M9, M12) and 30mL of whole blood will be taken at each visit. The duration of the study for the 7 other patients will be 1 day. |
whole blood sample
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
immunological : to qualify and quantify by confocal microscopic techniques and flow cytometry lymphocyte abnormalities
Time Frame: up to 1 year
|
The assessment of the change in the proportion of lymphocytes at 1, 3, 6, 9 and 12 months as compared to Day 1:
|
up to 1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
immunological
Time Frame: up to 1 year
|
The assessment by immunophenotyping test ( flow cytometry) of the change at 1, 3, 6, 9 and 12 months as compared to Day 1 of:
|
up to 1 year
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Odile LAUNAY, MD, PHD, CIC 1417 Clinical Center Investigation - Cochin Hospital, AP-HP
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- RNA Virus Infections
- Virus Diseases
- Blood-Borne Infections
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- Disease Attributes
- Slow Virus Diseases
- HIV Infections
- Infections
- Communicable Diseases
- Acquired Immunodeficiency Syndrome
Other Study ID Numbers
- PREDIACC
- 2018-A02025-50 (Registry Identifier: ID-RCB)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infections
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoUniversity of California, Los Angeles; University of Southern California; California... and other collaboratorsCompleted
-
Gérond'ifRecruiting
-
University of California, DavisCompleted
-
University of California, San DiegoNational Center for Complementary and Integrative Health (NCCIH)CompletedHIV PositiveUnited States
-
University of ChicagoUniversity of Athens; National Development and Research Institutes, Inc.Completed
-
HIV Prevention Trials NetworkNational Institute on Drug Abuse (NIDA); National Institute of Allergy and...CompletedHIV PositiveIndonesia, Ukraine, Vietnam
-
University of ZimbabweCompleted
-
Florida International UniversityCompleted
-
Boston Children's HospitalNational Institute on Minority Health and Health Disparities (NIMHD)Completed
Clinical Trials on biological sample
-
New York Stem Cell Foundation Research InstituteSilverstein FoundationRecruitingHealthy | Parkinson Disease | Gaucher Disease | GBA Gene MutationUnited States
-
University Hospital, BrestNot yet recruitingRepeated Spontaneous Miscarriages | Fetal Deaths in UteroFrance
-
Assistance Publique - Hôpitaux de ParisInstitut National de la Santé Et de la Recherche Médicale, France; ScreenCell; Celen... and other collaboratorsUnknownMelanoma | Circulating Tumor CellFrance
-
University Hospital, LilleRecruitingEosinophilia | Hypereosinophilic SyndromeFrance
-
Institut Hospitalo-Universitaire Méditerranée InfectionUniversity Hospital, MarseilleUnknown
-
Fondazione IRCCS Ca' Granda, Ospedale Maggiore...University of Milan; Italian Air Force; A-Tono; Ministry of Defense, ItalyRecruitingCardiovascular Risk Factor | Discogenic Pain | Neuroplasticity | Epigenetic Changes | Stress Physiological | Space Maintenance | Oxidative Injury | LONGEVITY 1 | NGSItaly
-
Exscientia GmbHAGO Research GmbHRecruitingEpithelial Ovarian CancerAustria, Germany
-
University Hospital Center of MartiniqueUniversity Hospital of GuadeloupeTerminatedHIV Infections | Zika Virus InfectionGuadeloupe, Martinique
-
Centre Hospitalier Universitaire de BesanconCompletedHuman Papillomavirus InfectionFrance